查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1715781

患者來源異質骨移植/PDX 模型市場（按類型、腫瘤類型、研究類型、植入方法、應用和最終用戶分類）—2025 年至 2030 年全球預測

Patient-Derived Xenograft/PDX Model Market by Type, Tumor Type, Study Type, Implantation Method, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023 年病患來源異質骨移植/PDX 模型市場價值為 3.8338 億美元，預計 2024 年將成長至 4.2904 億美元，複合年成長率為 12.27%，預計到 2030 年將達到 8.6231 億美元。

主要市場統計數據
基準年2023年 3.8338億美元
預計2024年 4.2904億美元
預測年份 2030 8.6231億美元
複合年成長率（%） 12.27%

患者來源的異種移植模型領域的不斷發展深刻地改變了臨床前研究和藥物開發的範式。這種將人類腫瘤組織移植到免疫力缺乏動物體內的創新方法已迅速發展成為轉化腫瘤學的重要工具。該技術模擬人類腫瘤微環境的能力越來越強，因此被認為提供了評估治療效果和抗藥性的寶貴平台。隨著全球趨勢日益轉向個人化醫療，PDX 模型不僅減輕了傳統體外系統的局限性，也為更深入了解癌症複雜的生物學鋪平了道路。本報告探討了推動 PDX 模型在一系列應用中採用的歷史背景、基礎科學和市場動態。我們的深入分析將嚴謹的科學研究與市場洞察相結合，幫助讀者理解 PDX 模型的複雜細微差別。綜合研究數據和分析框架的整合使專家和決策者對現有的挑戰和新興機會有了深入的了解，為這一變革性的生物醫學研究領域的持續創新和投資奠定了基礎。

改變病患來源的異質骨移植/PDX 模型市場

近年來，技術創新、不斷發展的法律規範以及對更具預測性的臨床前測試模型的穩定需求，導致了 PDX 模型市場發生了變革性的變化。這種轉變源於人們越來越認知到基於傳統細胞株的模型的缺點，以及對忠實重現人類腫瘤生物學的系統的迫切需求。基因工程和成像技術的進步進一步提高了 PDX 研究的精確度和可重複性，使學術界和工業界的研究人員能夠克服複雜的腫瘤學挑戰。

市場參與者正在利用將高級數據分析與即時監控相結合的整合平台，為治療反應提供前所未有的見解。重點是簡化實驗工作流程，以減少週轉時間和成本，從而促進對新癌症類型和治療方法的敏捷反應。隨著研究人員不斷努力根據患者的個別情況量身定做治療方法，市場正在大力轉向個人化醫療。這種轉變不僅要求臨床前評估更加精確，而且需要研究機構、生技公司和監管機構之間加強合作，最終為癌症研究和藥物開發樹立新的標準。

全面的關鍵細分市場洞察

PDX 模型市場的細分揭示了清晰的模式，為當前行業趨勢提供了可行的見解。基於類型的分析區分了小鼠和大鼠模型，突出了與每種動物系統相關的細微差別和特定優勢。透過腫瘤類型的視角，可以研究多種癌症，包括胃腸道癌症、婦科癌症、血液癌症、呼吸系統癌症和泌尿系統癌症，解決臨床表現中固有的異質性。調查方法細分包括體外、體內和體內方法，每種方法在模擬人類生物反應方面都有獨特的優勢。此外，根據植入方法區分模型突顯了異位、原位和皮下方法在提高實驗結果的有效性和精確度方面的重要性。

市場內的應用同樣多樣化，涵蓋基礎癌症研究、生物標記發現、基因組和分子研究、個人化醫療、臨床前藥物評估和腫瘤微環境分析。學術研究機構、癌症研究中心以及製藥和生物技術公司在這些模型的測試、檢驗和最終臨床轉化中發揮重要作用。這種多面向的細分方法凸顯了這個動態領域的研究界的專業知識深度和互聯互通性。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 癌症發生率上升推動了對先進臨床前模型的需求，以促進藥物研發
      • 增加政府對腫瘤學研究的投入與資金
      • 將PDX模型引入精準醫療，改善病患預後
    • 限制因素
      • 對 PDX 模型的不穩定性及高成本影響的擔憂
    • 機會
      • 策略合作與夥伴關係加速抗癌藥物研發
      • 在藥物測試中整合先進的分析平台和PDX模型
    • 任務
      • 限制在研究中使用病人來源異種移植模型的倫理問題和法規
  • 市場區隔分析
    • 類型：遺傳相似性增強了小鼠模型在轉化腫瘤學研究中的作用
    • 腫瘤類型：PDX 模型在血液系統癌症中的應用越來越廣泛，因為它們可以在基因和表現型上緊密模擬人類疾病。
    • 研究類型：透過準確重現人類腫瘤生物學，增強臨床前癌症研究的體內模型
    • 植入方法：皮下植入因其在研究環境中的簡單性和實用性而被擴大採用。
    • 應用：PDX 模型透過精確的癌症模擬促進臨床前藥物評估
    • 最終用戶：製藥和生物技術公司利用患者來源的異種移植/PDX 模型推動藥物開發的創新
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 病患來源異質骨移植/PDX 模型市場（按類型）

  • 小鼠模型
  • 大鼠模型

7. 病人異質骨移植/PDX 模型市場（依腫瘤類型）

  • 胃腸道
  • 婦科
  • 血液學
  • 呼吸系統
  • 泌尿系統

8. 病人異質骨移植/PDX 模型市場研究（按類型）

  • 體外
  • 體外
  • 體內

9. 病人來源異質骨移植/PDX 模型市場（依移植方法）

  • 異位
  • 原位
  • 皮下

第 10 章 患者異質骨移植/PDX 模型市場（按應用）

  • 基金會癌症研究
  • 生物標記發現
  • 基因組和分子研究
  • 個人化醫療
  • 臨床前藥物評價
  • 腫瘤微環境分析

第 11 章 病患異質骨移植/PDX 模型市場（依最終使用者）

  • 學術研究所
  • 癌症研究中心
  • 製藥和生物技術公司

12. 美洲患者異質骨移植/PDX 模型市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13. 亞太地區病患來源異質骨移植移植/PDX 模型市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

14. 歐洲、中東和非洲病患來源異質骨移植/PDX 模型市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abnova Corporation
  • Altogen Labs
  • Biocytogen
  • BioDuro LLC
  • BioReperia AB
  • Certis Oncology Solutions
  • Champions Oncology, Inc.
  • Charles River Laboratories International, Inc.
  • Creative Animodel
  • Creative Biolabs
  • Crown Bioscience by JSR Corporation
  • EPO Berlin-Buch GmbH
  • GemPharmatech Co. Ltd.
  • Genesis Drug Discovery & Development
  • Hera Biolabs
  • HOIST Co.,Ltd.
  • InnoSer
  • Inotiv, Inc.
  • Laboratory Corporation of America Holdings
  • LIDE Shanghai Biotech, Ltd
  • Mediford Corporation by PHC Holdings Corporation
  • Oncodesign Services
  • Shanghai ChemPartner
  • Shanghai Medicilon Inc.
  • TheraIndx Lifesciences Pvt. Ltd.
  • Urosphere SAS
  • WuXi AppTec Co., Ltd.
  • Xentech
Product Code: MRR-FF1601152744

The Patient-Derived Xenograft/PDX Model Market was valued at USD 383.38 million in 2023 and is projected to grow to USD 429.04 million in 2024, with a CAGR of 12.27%, reaching USD 862.31 million by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 383.38 million
Estimated Year [2024] USD 429.04 million
Forecast Year [2030] USD 862.31 million
CAGR (%) 12.27%

The evolving field of patient-derived xenograft models has significantly reshaped preclinical research and drug development paradigms. This innovative approach, which involves implanting human tumor tissues into immunocompromised animals, has swiftly developed into a vital tool for translational oncology. The methodology is gaining respect for its enhanced ability to mimic the human tumor microenvironment, thereby providing an invaluable platform for evaluating therapeutic efficacy and drug resistance. As global healthcare trends increasingly shift towards personalized medicine, PDX models not only mitigate the limitations of traditional in vitro systems but also pave the way for deeper insights into complex cancer biology. This report explores the historical context, underlying science, and market dynamics that continue to drive the adoption of these models across a range of applications. Detailed analyses that blend rigorous scientific inquiry with market trend insights guide readers through the intricate nuances of PDX models. The integration of comprehensive research data and analytical frameworks provides experts and decision-makers with a robust understanding of existing challenges and emerging opportunities, setting the stage for continued innovation and investment in this transformative area of biomedical research.

Transformative Shifts in the PDX Model Market Landscape

Recent years have seen transformative shifts in the PDX model market driven by technological innovation, evolving regulatory frameworks, and the steady demand for more predictive preclinical testing models. This transformation is rooted in the increasing recognition of the shortcomings of conventional cell-line based models and the compelling need for systems that closely replicate human tumor biology. Progressive advancements in genetic engineering and imaging technologies have further bolstered the precision and reproducibility of PDX studies, ensuring that both academic and industrial research avenues are well-equipped to navigate complex oncology challenges.

Market players are capitalizing on integrated platforms that combine advanced data analytics with real-time monitoring, offering unprecedented insights into therapeutic responses. There is a pronounced emphasis on streamlining experimental workflows to reduce turnaround time and cost, which in turn fosters a more agile response to emerging cancer types and treatment modalities. As researchers continually strive to tailor therapies to individual patient profiles, the market is experiencing a profound pivot towards personalized medicine. This shift not only demands higher accuracy in preclinical evaluation but also necessitates robust collaboration between research institutions, biotechnology companies, and regulatory bodies, ultimately setting a new standard for cancer research and drug development.

Comprehensive Key Segmentation Insights

The segmentation of the PDX model market reveals distinct patterns that offer actionable insights into current industry trends. An analysis based on type differentiates between mice models and rat models, highlighting the nuances and specific advantages associated with each animal system. When viewed through the lens of tumor type, research encompasses a diverse range that includes gastrointestinal, gynecological, hematological, respiratory, and urological cancers, thereby addressing the heterogeneity inherent in clinical presentations. The study type segmentation covers ex-vivo, in-vitro, and in-vivo methodologies, each providing unique strengths when it comes to simulating human biological responses. Furthermore, distinguishing models based on the implantation method shows the importance of heterotopic, orthotopic, and subcutaneous approaches in refining the relevance and accuracy of experimental outcomes.

Applications within the market are equally diverse, spanning basic cancer research, biomarker discovery, genomic and molecular studies, personalized medicine, preclinical drug evaluation, and tumor microenvironment analysis. End-user segmentation adds another important layer of insight, with academic research institutes, cancer research centers, and pharmaceutical and biotechnology companies each playing critical roles in the testing, validation, and eventual clinical translation of these models. Such a multifaceted segmentation approach underscores the depth of specialization and the interconnected nature of the research community in this dynamic field.

Based on Type, market is studied across Mice Models and Rat Models.

Based on Tumor Type, market is studied across Gastrointestinal, Gynecological, Hematological, Respiratory, and Urological.

Based on Study Type, market is studied across Ex-vivo, In-vitro, and In-vivo.

Based on Implantation Method, market is studied across Heterotopic, Orthotopic, and Subcutaneous.

Based on Application, market is studied across Basic Cancer Research, Biomarker Discovery, Genomic & Molecular Studies, Personalized Medicine, Preclinical Drug Evaluation, and Tumor Microenvironment Analysis.

Based on End-User, market is studied across Academic Research Institutes, Cancer Research Centers, and Pharmaceutical & Biotechnology Companies.

Regional Insights Supporting Global Market Trends

Geographical analysis of the PDX model market illustrates a robust, multi-regional growth narrative with significant contributions emerging from several key territories. In the Americas, robust investment in biomedical research infrastructure and supportive governmental policies continue to drive advancements. Meanwhile, regions encompassing Europe, the Middle East and Africa are increasingly prioritizing translational research, with a greater alignment towards personalized treatment approaches and more stringent regulatory oversight supporting higher quality preclinical evaluations. Asia-Pacific stands out as a vibrant hub of innovation, supported by substantial investment in biotechnology and an expanding base of both clinical and academic research institutions. The convergence of these regional dynamics not only creates a fertile ground for collaborative research but also reinforces global standards through data sharing and cross-border partnerships.

Collectively, these regional insights point to a future where market expansion will be bolstered by a unified approach to research excellence. The confluence of diverse regional capabilities ensures that the benefits of PDX models are realized on a global scale, thereby supporting a more integrated and responsive healthcare system worldwide.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Insightful Analysis of Leading Market Players

The competitive landscape in the PDX market is defined by a robust roster of companies that continue to push the boundaries of preclinical research and drug development. Key market players include Abnova Corporation, Altogen Labs, Biocytogen, BioDuro LLC, BioReperia AB, Certis Oncology Solutions, Champions Oncology, Inc., Charles River Laboratories International, Inc., Creative Animodel, Creative Biolabs, Crown Bioscience by JSR Corporation, EPO Berlin-Buch GmbH, GemPharmatech Co. Ltd., Genesis Drug Discovery & Development, Hera Biolabs, HOIST Co.,Ltd., InnoSer, Inotiv, Inc., Laboratory Corporation of America Holdings, LIDE Shanghai Biotech, Ltd, Mediford Corporation by PHC Holdings Corporation, Oncodesign Services, Shanghai ChemPartner, Shanghai Medicilon Inc., TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and Xentech.

These organizations have strategically capitalized on technological innovations and deep scientific expertise to address an increasingly competitive market environment. Their ongoing investments in research and development, persistent focus on quality and scalability, and commitment to forging strategic collaborations have been pivotal in expanding their respective portfolios. By maintaining a forward-thinking approach, these leaders ensure that their platforms remain at the cutting edge, thereby contributing significantly to the evolution of preclinical cancer research. Their efforts not only drive market growth but also inspire emerging players to adopt more rigorous standards in the pursuit of clinical excellence.

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Biocytogen, BioDuro LLC, BioReperia AB, Certis Oncology Solutions, Champions Oncology, Inc., Charles River Laboratories International, Inc., Creative Animodel, Creative Biolabs, Crown Bioscience by JSR Corporation, EPO Berlin-Buch GmbH, GemPharmatech Co. Ltd., Genesis Drug Discovery & Development, Hera Biolabs, HOIST Co.,Ltd., InnoSer, Inotiv, Inc., Laboratory Corporation of America Holdings, LIDE Shanghai Biotech, Ltd, Mediford Corporation by PHC Holdings Corporation, Oncodesign Services, Shanghai ChemPartner, Shanghai Medicilon Inc., TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, WuXi AppTec Co., Ltd., and Xentech. Actionable Recommendations for Industry Leaders

For industry leaders looking to harness the potential of PDX models, several actionable strategies emerge from current market trends. Optimizing research pipelines by investing in state-of-the-art imaging, genetic profiling, and data integration tools can significantly enhance preclinical validation and streamline drug development processes. Enhancing collaborative networks with leading academic institutions and clinical research centers will also be crucial in accessing real-world insights and accelerating translational research.

It is recommended that companies invest in robust quality control measures and standardization protocols to increase the reproducibility and reliability of their models. Broadening the spectrum of tumor types and refining implantation methodologies can further boost the clinical relevance of studies, thereby offering more targeted insights for personalized medicine initiatives. Leaders should also consider strategic partnerships and joint ventures as pivotal avenues for expanding their technological capabilities and accessing untapped markets. Finally, a dedicated focus on regulatory intelligence will enable organizations to navigate evolving legal frameworks more effectively, ensuring seamless integration of innovative approaches within established clinical paradigms.

Conclusion and Forward-Looking Perspective

In summing up, the landscape of patient-derived xenograft models represents a transformative and dynamic segment within the broader realm of oncology research and drug development. The integration of advanced biological models with cutting-edge technologies has paved the way for an era where preclinical assessments are more predictive and clinically relevant than ever before. This evolution not only underscores the importance of PDX models as a cornerstone for modern cancer research but also points to a future marked by enhanced precision, greater personalization, and more rapid translational outcomes.

As the market continues to evolve, stakeholders across academia, industry, and regulatory agencies must embrace the opportunities born of this convergence. A concerted effort in addressing experimental challenges, fine-tuning methodological approaches, and fostering strategic research partnerships will be key to unlocking further advancements. The journey ahead promises exciting developments, laying a robust foundation for innovations that are set to redefine therapeutic paradigms and ultimately improve patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in cancer prevalence amplifying the need for advanced preclinical models to enhance drug discovery
      • 5.1.1.2. Increased government initiatives and fundings for oncology research
      • 5.1.1.3. Incorporation of PDX models in precision medicine for enhanced patient outcomes
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with instability and high-cost implications of PDX models
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic collaborations and partnership to accelerate cancer drug development
      • 5.1.3.2. Integration of advanced analytical platforms with PDX models in drug testing
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical concerns and regulations limiting the use of patient-derived xenograft models in research
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Genetic similarity enhances mice model's role in translational oncology research
    • 5.2.2. Tumor Type: The ability of PDX models to closely mimic the human disease in genetic and phenotypic aspects increases the usage in hematological cancers
    • 5.2.3. Study Type: In-vivo Models enhancing preclinical cancer research through accurate replication of human tumor biology
    • 5.2.4. Implantation Method: The increasing adoption of subcutaneous implantation is driven by its simplicity and practicality in research settings
    • 5.2.5. Application: PDX models advancing preclinical drug evaluation with accurate cancer simulation
    • 5.2.6. End-User: Driving innovation in drug development with Patient-Derived Xenograft/PDX models in pharmaceutical and biotechnology companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Patient-Derived Xenograft/PDX Model Market, by Type

  • 6.1. Introduction
  • 6.2. Mice Models
  • 6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

  • 7.1. Introduction
  • 7.2. Gastrointestinal
  • 7.3. Gynecological
  • 7.4. Hematological
  • 7.5. Respiratory
  • 7.6. Urological

8. Patient-Derived Xenograft/PDX Model Market, by Study Type

  • 8.1. Introduction
  • 8.2. Ex-vivo
  • 8.3. In-vitro
  • 8.4. In-vivo

9. Patient-Derived Xenograft/PDX Model Market, by Implantation Method

  • 9.1. Introduction
  • 9.2. Heterotopic
  • 9.3. Orthotopic
  • 9.4. Subcutaneous

10. Patient-Derived Xenograft/PDX Model Market, by Application

  • 10.1. Introduction
  • 10.2. Basic Cancer Research
  • 10.3. Biomarker Discovery
  • 10.4. Genomic & Molecular Studies
  • 10.5. Personalized Medicine
  • 10.6. Preclinical Drug Evaluation
  • 10.7. Tumor Microenvironment Analysis

11. Patient-Derived Xenograft/PDX Model Market, by End-User

  • 11.1. Introduction
  • 11.2. Academic Research Institutes
  • 11.3. Cancer Research Centers
  • 11.4. Pharmaceutical & Biotechnology Companies

12. Americas Patient-Derived Xenograft/PDX Model Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Certis Oncology unveils AI-driven chatbot to enhance cancer research insights and PDX model efficiency
    • 15.3.2. UCLB and CancerTools.org partnership enhances new NSCLC PDX models development
    • 15.3.3. Champions Oncology announces licensing agreement with Weill Cornell Medicine
    • 15.3.4. REM-422 demonstrates tumor regression in ACC PDX models at 2024 symposium
    • 15.3.5. Charles River Laboratories transforming oncology research with PDX models and digital twins at AACR 2024
    • 15.3.6. Crown Bioscience has announced new preclinical and translational oncology data at the AACR 2024
    • 15.3.7. ProteinQure unveils breakthrough PDC showcasing exceptional efficacy in diverse PDX models
    • 15.3.8. InVivo Biosystems and BioReperia partners to transform cancer drug development
    • 15.3.9. Kiyatec and XenoSTART collaborated to help reduce drug development costs
    • 15.3.10. Soteria Precision Medicine Foundation partners with Certis Oncology Solutions
  • 15.4. Strategy Analysis & Recommendation
    • 15.4.1. WuXi AppTec Co., Ltd.
    • 15.4.2. Crown Bioscience by JSR Corporation
    • 15.4.3. Mediford Corporation by PHC Holdings Corporation
    • 15.4.4. Charles River Laboratories International, Inc.

Companies Mentioned

  • 1. Abnova Corporation
  • 2. Altogen Labs
  • 3. Biocytogen
  • 4. BioDuro LLC
  • 5. BioReperia AB
  • 6. Certis Oncology Solutions
  • 7. Champions Oncology, Inc.
  • 8. Charles River Laboratories International, Inc.
  • 9. Creative Animodel
  • 10. Creative Biolabs
  • 11. Crown Bioscience by JSR Corporation
  • 12. EPO Berlin-Buch GmbH
  • 13. GemPharmatech Co. Ltd.
  • 14. Genesis Drug Discovery & Development
  • 15. Hera Biolabs
  • 16. HOIST Co.,Ltd.
  • 17. InnoSer
  • 18. Inotiv, Inc.
  • 19. Laboratory Corporation of America Holdings
  • 20. LIDE Shanghai Biotech, Ltd
  • 21. Mediford Corporation by PHC Holdings Corporation
  • 22. Oncodesign Services
  • 23. Shanghai ChemPartner
  • 24. Shanghai Medicilon Inc.
  • 25. TheraIndx Lifesciences Pvt. Ltd.
  • 26. Urosphere SAS
  • 27. WuXi AppTec Co., Ltd.
  • 28. Xentech

LIST OF FIGURES

  • FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET MULTI-CURRENCY
  • FIGURE 2. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET MULTI-LANGUAGE
  • FIGURE 3. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
  • FIGURE 4. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 23. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 29. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
  • TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY EX-VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VITRO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IN-VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HETEROTOPIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ORTHOTOPIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GENOMIC & MOLECULAR STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG EVALUATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STUDY TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY IMPLANTATION METHOD, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 285. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 286. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023